A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma

作者
Pamela Sue Becker,Ted Alan Gooley,Kathy Lilleby,Damian J. Green,Nicholas R. Burwick,Christine Wallace,Theodore Kim,Kiarash Kojouri,Erin M. Nelli,William Bensinger
出处
期刊:Blood [Elsevier BV]
卷期号:120 (21): 5038-5038
标识
DOI:10.1182/blood.v120.21.5038.5038
摘要

Abstract Abstract 5038 Background: Combination regimens have been highly effective in multiple myeloma. Based on our results with the combination of bortezomib, cyclophosphamide, dexamethsone (Bensinger et al Br J Haematol 2010), we added liposomal doxorubicin to assess whether we could improve response as well as evaluate a weekly combination regimen at our academic center and network affiliated sites in the community. The trial is registered as NCT00849251. Methods: We initially evaluated the regimen in the relapsed setting for toxicity and found it to be well tolerated in 6 patients, then moved to newly diagnosed patients, with the intent that the regimen would serve as induction chemotherapy in preparation for autologous stem cell transplant for transplant-eligible patients. The dosing was bortezomib 1. 6 mg/m2 IV, cyclophosphamide 300 mg/m2 IV, and dexamethasone 40 mg po, days 1, 8, 15, and a single dose of liposomal doxorubicin 30 mg/m2 on day 8 per 28 day cycle. Patients received a maximum of 4 cycles of therapy and the primary endpoints were safety and response at the end of treatment. Results: A total of 31 out of the planned 45 patients (both newly diagnosed and relapsed) were enrolled, as the trial was ended early due to inability to obtain liposomal doxorubicin (Doxil®) for a period of 6 months. One of the relapsed patients was administratively withdrawn after the cycle 1 day 1 treatment. For the remaining 5 relapsed patients who received 2–4 cycles of treatment, the responses were 1 VGPR that was only immunofixation positive, 1 PR and 3 stable disease (SD). For the 24 patients with newly diagnosed MM who completed 1–4 cycles of treatment, there were 2 complete remissions (CRs), 5 VGPRs (2 of which were only immunofixation positive), 11 PRs, and 6 SD for an overall (CR+VGPR+PR) response rate of 75%. Five patients did not complete 4 cycles of therapy, one due to massive pulmonary embolism, one because of need for radiation for intractable back pain during cycle 2 despite marked serological response, and 3 due to stable disease with plateau in response. Of the 25 patients who received BCDD as initial therapy, there have been 3 deaths to date, one due to massive pulmonary embolism on day 13 of the first cycle of treatment, without known history of hypercoagulable risk, one at 7. 7 months of unknown cause, and one at 15. 3 months of progressive disease, resulting in an estimated overall survival of 86% at 2 years from start of therapy. Median follow-up among the 22 survivors is 16. 6 months (range, 8. 1 to 26. 8 months). One patient with a known central line associated deep venous thrombosis in the relapsed group did not exhibit progression of thrombosis off warfarin during therapy. After enrollment of the first 9 patients, an amendment was filed for subsequent patients to receive aspirin prophylaxis, or if at high risk by criteria suggested by Palumbo et al for prophylaxis for MM patients on imids, with low molecular weight heparin or warfarin. Other adverse events that were attributed to investigational regimen include grade 3 hand/foot syndrome (2), infection without neutropenia (1), urinary tract infection (1), and gastrointestinal hemorrhage due to Mallory-Weiss tear (1). Twenty-one patients who completed therapy went on to successful mobilization and collection of peripheral blood stem cells, and autologous or tandem autologous (2) or tandem autologous-minimal myeloablative allogeneic stem cell transplant (7). Two of the 21 patients have died (one at 2. 1 months after first autologous transplant from unknown cause, and one at 9. 8 months from progressive disease). Median follow-up after first autologous transplant among the 19 survivors is 13. 4 months (range, 1. 1 to 20. 4 months). Summary: The 4 drug BCDD regimen exhibited a 75% overall response rate after 4 cycles, with no progression during treatment, was able to be administered weekly in an outpatient setting of both academic and community hematologists and oncologists, and successfully prepared patients for autologous stem cell transplant. Disclosures: Becker: Millennium: Research Funding. Bensinger:Millennium: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘艺珍完成签到,获得积分10
刚刚
orixero的应助被科研通管家采纳,获得10
刚刚
丘比特的应助被科研通管家采纳,获得10
刚刚
Ava的应助被科研通管家采纳,获得10
刚刚
Hello的应助被科研通管家采纳,获得10
刚刚
Ava的应助被科研通管家采纳,获得10
1秒前
上官若男的应助被科研通管家采纳,获得10
1秒前
无辜的擎汉完成签到,获得积分10
1秒前
1秒前
orixero的应助被科研通管家采纳,获得10
1秒前
hua发布了新的文献求助10
1秒前
观潮发布了新的文献求助10
1秒前
FashionBoy的应助被科研通管家采纳,获得10
1秒前
Lucas的应助被科研通管家采纳,获得10
1秒前
在水一方的应助被科研通管家采纳,获得10
1秒前
hjin完成签到,获得积分10
1秒前
wanci的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
2秒前
酷波er的应助被科研通管家采纳,获得10
2秒前
谢老师发布了新的文献求助10
2秒前
JamesPei的应助被科研通管家采纳,获得10
2秒前
斯文的友蕊完成签到,获得积分10
2秒前
molihuakai的应助被科研通管家采纳,获得10
2秒前
上官若男的应助被xrk采纳,获得30
2秒前
2秒前
科目三的应助被科研通管家采纳,获得10
2秒前
yanjing完成签到 ,获得积分10
2秒前
李爱国的应助被科研通管家采纳,获得10
3秒前
NICAI的应助被科研通管家采纳,获得10
3秒前
烟花的应助被科研通管家采纳,获得10
3秒前
烟花的应助被科研通管家采纳,获得10
3秒前
科研通AI6.4的应助被CS采纳,获得10
3秒前
小二郎的应助被科研通管家采纳,获得10
3秒前
3秒前
大个的应助被fjsfff采纳,获得10
3秒前
04d的应助被科研通管家采纳,获得10
3秒前
3秒前
我不李解的应助被科研通管家采纳,获得20
3秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315